CPT code 0248U designates a Proprietary Laboratory Analyses (PLA) test—Kiyatec® Inc.'s 3D Predict Glioma—that uses patient-derived tumor cells cultured in a three-dimensional platform to forecast tumor response to 12 oncology drugs. As a PLA code, 0248U applies to a single, manufacturer-specific assay and provides a discrete reporting mechanism for payers and providers evaluating advanced functional precision oncology diagnostics. Nationally, PLA codes like 0248U matter because they enable tracking and payment clarity for proprietary assays that lack generic CPT equivalents.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context of the assay, typical settings where the service is performed, and the scope of services the code represents. The publication summarizes available benchmarks and policy considerations for proprietary laboratory tests, clarifies billing scope and service type, and outlines payer coverage landscape where available. Data not available in the input is noted explicitly. The content is intended for national audiences including payers, laboratory administrators, clinicians involved in neuro-oncology care, and revenue cycle professionals seeking concise clarity on what CPT code 0248U represents.